Register For UpdatesAbout IC-HEP

Registration

Leave this field empty
Back to links
Back to links

Global Education

Expert Perspectives: Highlights on HCV from EASL 2017

Expert Perspectives: Highlights on HCV from EASL 2017

Jasmohan Bajaj, MD & Rajender Reddy, MD

Endorsed by:

Expert Perspectives: Highlights on HCV from EASL 2017

Seng Gee Lim, MD & Teerha Piratvisuth, MD

Endorsed by:

Expert Perspectives: Highlights on HCV from EASL 2017

Funmilayo Lesi, MD & Hailemichael Desalegn, MD

Expert Perspectives: Highlights on HCV from EASL 2017

Milagros Davalos, MD & Marcelo Silva, MD

Endorsed by:

APASL 2017 Conference - Shanghai, China

Countries and Regions Waiting Approval for DAAs: What is the Best Management Strategies?

Ming-Lung Yu

Therapy of HCV: Remaining Challenges and Future Opportunities

T. Jake Liang, MD

Clinical Decision Making with Nucs in 2016/2017

Professor Seng Gee Lim

Developing Countries and Regions: The role of generic Drugs

Professor Salimur Rahman

Finite Treatment with NUCs

Thomas Berg

Expert Perspectives: Highlights on HCV from AASLD 2016

Expert Perspectives: Highlights on HCV from AASLD 2016

Nancy Reau, MD & Zobair Younossi, MD

Endorsed by:

Expert Perspectives: Highlights on HCV from AASLD 2016

Maria Buti, MD & Adrian Gadano, MD

Endorsed by:

Expert Perspectives: Highlights on HCV from AASLD 2016

Mary Afihene, MD & Ashraf Omar, MD

Expert Perspectives: Highlights on HCV from AASLD 2016

Diana Alcantara-Payawal, MD & Ajay Duseja, MD

Endorsed by:

AUDIOCAST of the CLDF CME Symposium at UEGW 2016 - Vienna, Austria

Get Ready for the Global Epidemic of NASH: Evolving Diagnosis and Treatment Strategies

Vlad Ratziu, MD, PhD & Zobair M. Younossi, MD, MPH

Supported by Intercept
Pharmaceuticals, Inc.

Expert Perspectives on the Management of PBC: A Case-Based Approach

Cynthia Levy, MD & Gideon M. Hirschfield, MB BChir FRCP PhD

Supported by Intercept
Pharmaceuticals, Inc.

Challenges and Opportunities in the Management of Chronic Hepatitis C

Review of the Treatment of Hepatitis C Genotypes 2-6

David Bernstein, MD & Eugene Schiff, MD

Supported by: Bristol-Myers Squibb & Merck

HCV Resistance

Kimberly Brown, MD & Ira Jacobson, MD

Supported by: Bristol-Myers Squibb & Merck

Advances in Cirrhosis Management

Jasmohan Bajaj, MD & Nancy Reau, MD

Supported by: Bristol-Myers Squibb & Merck

HIV-HCV Coinfection

Fred Poordad, MD & Mark Sulkowski, MD

Supported by: Bristol-Myers Squibb & Merck

Renal Insufficiency

Robert Brown, MD & Paul Kwo, MD

Supported by: Bristol-Myers Squibb & Merck

Update on HCV Guidelines

Steven Flamm, MD & Robert Gish, MD

Supported by: Bristol-Myers Squibb & Merck

Expert Perspectives: Best of HCV - 2016 Spring Update

Expert Perspectives: Best of HCV - 2016 Spring Update

Paul Kwo, MD & Tram Tran, MD

Supported by: AbbVie, Bristol-Myers Squibb, Gilead Sciences, and Merck

Expert Perspectives: Best of HCV - 2016 Spring Update

V. Isakov, MD & K. Zhdanov, MD

Supported by: AbbVie, Bristol-Myers Squibb, and Gilead Sciences

Expert Perspectives: Best of HCV - 2016 Spring Update

H. Cheinquer, MD & M. Pessôa, MD

Supported by: AbbVie, Bristol-Myers Squibb, and Gilead Sciences

Expert Perspectives: Best of HCV - 2016 Spring Update

Y. Eguchi & M. Ono

Supported by: AbbVie, Bristol-Myers Squibb, and Gilead Sciences

APASL 2016 Conference - Tokyo, Japan

Barriers of HCV Treatment in Asia Pacific

Masao Omata

Supported by: AbbVie, Bristol-Myers Squibb, and Gilead Sciences

Presidential Lecture

Osamu Yokosuka

Supported by: AbbVie, Bristol-Myers Squibb, and Gilead Sciences

HCV Therapy-One Treatment for All Populations

Edward Gane

Supported by: AbbVie, Bristol-Myers Squibb, and Gilead Sciences

Interferon-Free Treatment of Hepatitis C in Patients with Cirrohosis Before and After Liver Transplant

Adrian Di Bisceglie, MD

Supported by: AbbVie, Bristol-Myers Squibb, and Gilead Sciences

APASL HCV Guidelines: Liver Transplantation

Geoffrey McCaughan, MD

Supported by: AbbVie, Bristol-Myers Squibb, and Gilead Sciences

Hepatitis B in Europe

E. Estrabaud and P. Marcellin

Supported by: AbbVie, Bristol-Myers Squibb, and Gilead Sciences

Clinical Outcomes of Anti Hepatitis C Therapy

Massimo Colombo

Supported by: AbbVie, Bristol-Myers Squibb, and Gilead Sciences

Therapy of HCV: Remaining Challenges and Future Opportunities

T. Jake Liang

Supported by: AbbVie, Bristol-Myers Squibb, and Gilead Sciences

New Therapies in HCV: Towards a Global Cure

Nezam Afdhal

Supported by: AbbVie, Bristol-Myers Squibb, and Gilead Sciences

Barriers of HCV Treatment in China

Lai Wei

Supported by: AbbVie, Bristol-Myers Squibb, and Gilead Sciences

Serum HBsAg and AFP Levels during Acute Hepatitis Flare of Chronic Hepatitis B: A New Look in the Natural Course and Antiviral Therapy

Yun-Fan Liaw

Supported by: AbbVie, Bristol-Myers Squibb, and Gilead Sciences

The 4th ASEAN Perspective in Liver Diseases (Thailand)

Plenary I: Screening of Viral Hepatitis and HCC: the Why and the How

R. Kim & T. Tanwandee

Supported by: AbbVie, Bristol-Myers Squibb, and Gilead Sciences 

Opening Ceremony

Supported by: AbbVie, Bristol-Myers Squibb, and Gilead Sciences 

Keynote Lecture I: Pharmacologic management of NASH: Towards a new paradigm

Leon Adams

Supported by: AbbVie, Bristol-Myers Squibb, and Gilead Sciences 

Symposium I: New paradigms in NAFLD

Supported by: AbbVie, Bristol-Myers Squibb, and Gilead Sciences 

Symposium II: Hepatitis C: Who to treat and with what

Supported by: AbbVie, Bristol-Myers Squibb, and Gilead Sciences 

Symposium III: Hepatitis C in special populations

Supported by: AbbVie, Bristol-Myers Squibb, and Gilead Sciences 

Case-based study: Practical Practice in the Management of HCV in Asia

Supported by: AbbVie, Bristol-Myers Squibb, and Gilead Sciences 

Plenary II: Hepatitis B Guidelines over the decades

Supported by: AbbVie, Bristol-Myers Squibb, and Gilead Sciences 

Symposium IV: New paradigms in the management of HBV

Supported by: AbbVie, Bristol-Myers Squibb, and Gilead Sciences 

Symposium V: Revisiting HCC: The 2016 evidence for Preventing HCC and Recurrence

Supported by: AbbVie, Bristol-Myers Squibb, and Gilead Sciences 

Keynote Lecture II: Occult HBV Infection

Rosmawati Mohamed

Supported by: AbbVie, Bristol-Myers Squibb, and Gilead Sciences 

NAFLD: problems beyond the liver

Supported by: AbbVie, Bristol-Myers Squibb, and Gilead Sciences 

New Paradigms in the Management of Hepatic Encephalopathy

Manuel Romero-Gomez

Supported by: AbbVie, Bristol-Myers Squibb, and Gilead Sciences 

Expert Perspectives: Best of HCV – 2015 Year End Update

EXPERT PERSPECTIVES: Best of HCV - 2015 Year End Update

T. Asselah, MD & M. Bourlière, MD

Supported by: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Inc.

EXPERT PERSPECTIVES: Best of HCV - 2015 Year End Update

Jinlin Hou, MD & Ke-Qin Hu, MD

Supported by: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Inc.

EXPERT PERSPECTIVES: Best of HCV - 2015 Year End Update

N. Sanchez, MD & R. Velazquez, MD

Supported by: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Inc.

2015 Education

LIVER SUMMIT SERIES

LIVER SUMMIT SERIES

Review of the WHO Guidelines for the Screening, Care, and
Treatment of Persons with HCV

Review of the WHO Guidelines for the Screening, Care, and Treatment of Persons with HCV

Raj Reddy, MD

Supported by: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Inc., and Merck

2015 Singapore Hepatitis Conference Coverage

How to evaluate the HCV patient in 2015 - What Parameters Are Still Important?

Samir R. Shah

Supported by: AbbVie, Bristol-Myers Squibb and Gilead Sciences

Therapeutic Strategies for HCV Non-Genotype 1

Fred Poordad, MD

Supported by: AbbVie, Bristol-Myers Squibb and Gilead Sciences

HCV Treatment options in Asia: A moving target

Prof. Teerha Piratvisuth

Supported by: AbbVie, Bristol-Myers Squibb and Gilead Sciences

HCV: Current SOTA of Management of Treatment Experienced Patients

Robert G. Gish, MD

Supported by: AbbVie, Bristol-Myers Squibb and Gilead Sciences

Treatment of HCV-HIV Co-Infection

Mitchell L. Shiffman, MD

Supported by: AbbVie, Bristol-Myers Squibb and Gilead Sciences

Picking the Winners and Future of HCV Treatment

Ed Gane

Supported by: AbbVie, Bristol-Myers Squibb and Gilead Sciences

HCV Current Practices in China, India, Indonesia, Malaysia, Myanmar, Singapore, Taiwan and Thailand

HCV Round table discussion

Supported by: AbbVie, Bristol-Myers Squibb and Gilead Sciences

Prevalence and Estimates Treatable Hepatitis B Patients in Asia

Pei-Jer Chen

Supported by: AbbVie, Bristol-Myers Squibb and Gilead Sciences

HBsAg loss: and achievable treatment target?

Pietro Lampertico

Supported by: AbbVie, Bristol-Myers Squibb and Gilead Sciences

How to use pegylated Interferon for Chronic Hepatitis B in 2015

Teerha Piratvisuth

Supported by: AbbVie, Bristol-Myers Squibb and Gilead Sciences

HBV quantitative sAg assay: Ready for Prime time? Yes

Robert G. Gish, MD

Supported by: AbbVie, Bristol-Myers Squibb and Gilead Sciences

Quantitative HBSAG is Not Ready for Clinical Use

Mitchell L. Shiffman, MD

Supported by: AbbVie, Bristol-Myers Squibb and Gilead Sciences

Chronic Hepatitis B Promising New Treatments

Ed Gane

Supported by: AbbVie, Bristol-Myers Squibb and Gilead Sciences

Chemotherapy and immunosuppressive therapy, pregnancy and hepatitis B

Ji-dong Jia, MD, PhD

Supported by: AbbVie, Bristol-Myers Squibb and Gilead Sciences

Hepatitis B Pre and Post Liver and Renal Transplant

Fred Poordad, MD

Supported by: AbbVie, Bristol-Myers Squibb and Gilead Sciences

Expert Perspectives: Best of HCV from EASL 2015 (Audiocasts)

Expert Perspectives: Best of HCV from EASL 2015

M. Buti, MD, PhD & L. Serfaty, MD

Supported by: AbbVie, Bristol-Myers Squibb, and Gilead Sciences

Expert Perspectives: Best of HCV from EASL 2015

M. Buti, MD, PhD & L. Serfaty, MD

Supported by: AbbVie, Bristol-Myers Squibb, and Gilead Sciences

Expert Perspectives: Best of HCV from EASL 2015

Expert Perspectives: Best of HCV from EASL 2015

D. Bernstein & M. Shiffman, USA

Supported by: AbbVie, Bristol-Myers Squibb, Gilead Sciences, and Merck

Expert Perspectives: Best of HCV from EASL 2015

M. Buti, MD, PhD & L. Serfaty, MD

Supported by: AbbVie, Bristol-Myers Squibb, and Gilead Sciences

Expert Perspectives: Best of HCV from EASL 2015

G. Foster, MD & C. Yurdaydin, MD

Supported by: AbbVie, Bristol-Myers Squibb, and Gilead Sciences

Expert Perspectives: Best of HCV from EASL 2015

S. Hamid, MD & A. Thompson, MD

Supported by: AbbVie, Bristol-Myers Squibb, and Gilead Sciences

The Advances in Chronic Hepatitis C: Management and Treatment

M. Pessoa, MD & M. Schechter, MD

2015 APASL Conference Coverage - Istanbul, Turkey

The Role of New Combination Therapies without Interferon

Wan-Long Chuang, MD

Supported by: AbbVie, Bristol-Myers Squibb, and Gilead Sciences

The impact of the treatment of HCV in developing Hepatocellular Carcinoma

Paul Kwo, MD

Supported by: AbbVie, Bristol-Myers Squibb, and Gilead Sciences

All-Oral 12-Week Combination Treatment With Daclatasvir and <br/>Sofosbuvir in Patients Infected With HCV Genotype 3: ALLY-3 Phase 3 Study

Trevor Hawkins, MD

Supported by: AbbVie, Bristol-Myers Squibb, and Gilead Sciences

The Differences in Antiviral Agents in the Treatment of Hepatitis B

Patrick Marcellin, MD

Supported by: AbbVie, Bristol-Myers Squibb, and Gilead Sciences

Interferon Treatment in Hepatitis C: Necessary or Not in Future Aspects?

Darrell Crawford, MD

Supported by: AbbVie, Bristol-Myers Squibb, and Gilead Sciences

APASL-EASL Joint Meeting Asian and European Perspective on Treatment of Hepatitis B and C

Alessio Aghemo, MD

Supported by: AbbVie, Bristol-Myers Squibb, and Gilead Sciences

Shortening Overall Treatment to 12 Weeks of Simeprevir Plus PR in Treatment-Naïve Chronic Hepatitis C Genotype 1 Patients: Assessment of Baseline and Week 2 on Treatment Predictors of SVR

Tarik Asselah, MD

Supported by: AbbVie, Bristol-Myers Squibb, and Gilead Sciences

2014 Education

WGO 2014

  • HCC: A Global Crisis Silent and Widely Ignored Douglas R. LaBrecque, MD Watch Slides
  • Hepatitis C Professor Aamir Ghafoor Khan Watch Slides

WGO Audiocasts 2014

  • Estado actual de la Hepatitis C en la Argentina Marcelo Silva, MD Watch Slides
  • Estado actual do manejo do HCV no Brasil Hugo Cheinquer, MD, PhD Watch Slides
  • Estado actual de manejo dela Hepatitis C en Chile Javier Brahm, MD Watch Slides

APASL STC: Pakistan 2014

  • Risk Factors for HCV Transmission in Pakistan Dr. Saeed Hamid Watch Slides
  • HCV Treatment at the Dawn of the DAA era Dr. Ashley Brown Watch Slides
  • IFN-free for Genotype 1 HCV: The Current Landscape Prof. Graham R. Foster Watch Slides

Best of HCV from AASLD 2014

  • Best of HCV from AASLD 2014 Mark Sulkowski, MD Watch Slides
  • Best of HCV from AASLD 2014 Kris Kowdley, MD Watch Slides
  • Best of HCV from AASLD 2014 Rosmawati Mohamed, MD Watch Slides
  • Best of HCV from AASLD 2014 Manuel Romero-Gomez, MD Watch Slides
  • Best of HCV from AASLD 2014 Victor de Ledinghen, MD, PhD Watch Slides
  • Best of HCV from AASLD 2014 Cihan Yurdaydin, MD Watch Slides
  • Best of HCV from AASLD 2014 Lai Wei, MD, PhD Watch Slides
  • Best of HCV from AASLD 2014 Vasily Isakov, MD Watch Slides

2014 ALEH Conference Coverage - Cancun, Mexico

  • Current treatment for chronic hepatitis C Hugo Cheinquer, MD PhD Watch
  • Future Treatment of Chronic Hepatitis C Michael Manns, MD Watch
  • Tratamientos actuales para Hepatitis B Crónica J. Francisco Sánchez-Avila, MD Watch
  • Management of Hepatitis C: in Latin America: A Case Based Discussion E. Ridruejo and M. Guimarães Watch
  • Sofosbuvir Rafael Esteban, MD Watch
  • ABT 450/r (Paritaprevir), Ombitasvir (ABT-267) and Dasabuvir (ABT-333) Kris Kowdley, MD Watch
  • Daclatasvir Adrián Gadano, MD Watch
  • SIMEPREVIR Tarik Asselah, MD, PhD Watch

2014 Singapore Hepatitis Conference Coverage

  • Introduction: Treatment of Hepatitis C in Asia: The Issues Seng Gee Lim, Singapore Watch
  • Hepatitis C Diseases Burden in Asia: Limitations and Prospects Pei-Jer Chen, Taiwan Watch
  • Management of Adverse Events Wei Lai, China Watch
  • Predictors of Response and Stopping Rules Henry Chan, China Watch
  • Do we still Need Interferon for the New DAA's Teerha Piratvisuth, Thailand Watch
  • The Promise of Interferon Free Therapy Raj Reddy, USA Watch
  • New Therapeutic Strategies Stefan Zeuzem, Germany Watch
  • Differences in Approaches - West vs. East Raj Reddy, USA Watch
  • Genotype 2 vs 3 Samir Shah, India Watch
  • Genotype 6 Qin Ning, China Watch
  • Treat now / Treat Later R. Gish & M. Schiffman, USA Watch
  • Treatment Failures Stefan Zeuzem, Germany Watch
  • Cirrhotic Patients Robert Gish, USA Watch
  • Transplant Patients Mitchell Shiffman, USA Watch
  • Co-infected Patients Jai Horng Kao, Taiwan Watch
  • Understanding Healthcare Systems in Asia Dan Yock Young, Singapore Watch
  • Access to New DAAs in Asia Samir Shah, India Watch
  • Cost Effectiveness Models for HCV Therapy Dan Yock Young, Singapore Watch
  • Conclusion and Algorithm for HCV Therapy in Asia Seng Gee Lim, Singapore Watch

Best of HCV from EASL 2014

  • Best of HCV from EASL 2014 Jordan Feld, MD Watch
  • Best of HCV from EASL 2014 Catherine Stedman, MD Watch Slides
  • Best of HCV from EASL 2014 Zobair Younossi, MD, MPH, FACG Watch Slides
  • Best of HCV from EASL 2014 Patrick Marcellin, MD Watch Slides
  • Best of HCV from EASL 2014 Savino Bruno, MD Watch Slides
  • Best of HCV from EASL 2014 Geoffrey Dusheiko, MD Watch Slides
  • Best of HCV from EASL 2014 Rafael Esteban, MD Watch Slides
  • Best of HCV from EASL 2014 Stefan Zeuzem, MD Watch Slides

2014 APASL Conference Coverage - Brisbane, Australia

  • Triple Therapy in 2013 and beyond in Asia Tawesak Tanwandee, MD Watch
  • Drug Resistance and Treatment Failure in Asia Masashi Mizokami, MD Watch
  • Hepatitis C - Current Treatments: What Can We Offer Patients Now? Domini Ray-Chaudhuri, MD Watch
  • Funding, access and infrastructure for new HCV therapies across Asia Pacific Charles Gore, President, WHA Watch
  • Public Health strategies to reduce liver disease in the Asia Pacific Region Charles Gore, President, WHA Watch
  • Optimizing triple therapy, and IFN/RBV free regimens Kazuaki Chayama Watch
  • Direct Acting Antivirals for HCV GT-1 State of Play in 2014 Ed Gane Watch
  • Hepatitis C virus lifecycle: What are the best drug targets? Michael Beard Watch
  • Hepatitis C Direct Acting Antivirals for Genotypes 2/3: State of Play 2014 Catherine Stedman Watch
  • Host genomics and HCV treatment response: IL-28B and beyond Alex Thompson Watch

Best of HCV from AASLD 2013

  • Best of HCV from AASLD 2013 Alessandra Mangia, MD Watch
  • Best of HCV from AASLD 2013 Stanislas Pol, MD Watch
  • Best of HCV from AASLD 2013 Michael Manns, MD Watch
  • Best of HCV from AASLD 2013 Maria Buti, MD Watch
  • Best of HCV from AASLD 2013 Michael Manns, MD Watch Slides
  • Best of HCV from AASLD 2013 Paul Kwo, MD Watch Slides
  • Best of HCV from AASLD 2013 Kimberly Brown, MD Watch Slides
  • Best of HCV from AASLD 2013 Darrell Crawford, MD Watch Slides

2013 APASL Conference Coverage - Singapore

  • Current Therapy and Changing Landscape in the Near Future Ed Gane Watch
  • How to Use Triple Therapy for Genotype 1 HCV Infection: Treatment-naÏve Patients Chun-Jen Liu, MD,PhD Watch
  • Treatment Experience Patients Rafael Esteban Watch
  • How to use Triple Therapy for HCV-1 Pre-Treatment Predictors - What to Test? Alex Thompson, MBBS, PhD, FRACP Watch
  • Lead in and On Treatment Response Indicators Fred Poordad, MD Watch
  • Chronic Hepatitis C - Whom Not to Treat Peter Ferenci Watch
  • Which Patients to Treat and Which to Keep? Patrick Marcellin Watch
  • Cirrhosis: Real Life Versus Clinical Trial Marc Bourliere, MD Watch
  • Monitoring and Stopping Rules Marc Ghany, MD Watch
  • Future Strategies: Direct Acting Antivirals Heiner Wedemeyer, MD Watch
  • Special Populations, Patients with Renal Disease, Post Renal Transplant, and Co-Infected Patients Samuel S. Lee, MD Watch
  • PI Triple Therapy – Treatment of Post Liver Transplant Recipients Norah Terrault, MD,MPH Watch
  • HCV Triple Therapy: Management of Side Effects Samuel S. Lee, MD Watch
  • Drug Interactions and DAA's Jacob George, MD Watch

HCV: Highlights From EASL 2013

  • HCV: Highlights From EASL 2013 Alex Thomspon, MBBS, PhD, FRACP Watch Slides
  • HCV: Highlights From EASL 2013 Fred Poordad, MD Watch Slides
  • HCV: Highlights From EASL 2013 Andrew J.Muir, MD Watch Slides
  • HCV: Highlights From EASL 2013 Seng Gee Lim, MD Watch Slides